Raynaud's Disease - MediQuest Receives NDA Response From FDA MediQuest Therapeutics, Inc. received a Complete Response letter from the U.S. Food and Drug Administration (FDA) Division of Cardiovascular and Renal Products for its New Drug Application (NDA) 22-241 (covering Vascana® [MQX-503], a proposed topical therapy for Raynaud's Disease). The application received priority review and the letter was received one day prior to the six-month PDUFA date of Oct. 25, 2008.
Source: www.medicalnewstoday.com
# posted by Network @ 11:00 AM
